REGENERON PHARMACEUTICALS, INC. Retained Earnings 2009-2026 | REGN
What is retained earnings?
Retained earnings represent the cumulative net income that has been reinvested in the business rather than distributed as dividends to shareholders.
What is REGENERON PHARMACEUTICALS, INC.'s current retained earnings?
REGENERON PHARMACEUTICALS, INC. (REGN) annual retained earnings for 2025 was $35.80B, a 13.02% increase from 2024. REGENERON PHARMACEUTICALS, INC. retained earnings for the quarter ending March 31, 2026 was $36.42B.
What was REGENERON PHARMACEUTICALS, INC.'s retained earnings in 2024?
REGENERON PHARMACEUTICALS, INC. annual retained earnings for 2024 was $31.67B, a 16.19% increase from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s retained earnings in 2023?
REGENERON PHARMACEUTICALS, INC. annual retained earnings for 2023 was $27.26B, a 16.96% increase from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year retained earnings CAGR?
REGENERON PHARMACEUTICALS, INC. retained earnings grew at a compound annual growth rate (CAGR) of 26.86% from FY2020 to FY2025, going from $10.89B to $35.80B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $35.80B | +13.0% | 10-K |
| FY2024 | $31.67B | +16.2% | 10-K |
| FY2023 | $27.26B | +17.0% | 10-K |
| FY2022 | $23.31B | +22.9% | 10-K |
| FY2021 | $18.97B | +74.1% | 10-K |
| FY2020 | $10.89B | +47.6% | 10-K |
| FY2019 | $7.38B | +40.5% | 10-K |
| FY2018 | $5.25B | +78.3% | 10-K |
| FY2017 | $2.95B | +68.6% | 10-K |
| FY2016 | $1.75B | +105.0% | 10-K |
| FY2015 | $852.7M | +293.6% | 10-K |
| FY2014 | $216.6M | +333.7% | 10-K |
| FY2013 | $-92.7M | +82.1% | 10-K |
| FY2012 | $-517.1M | +59.2% | 10-K |
| FY2011 | $-1.27B | -21.2% | 10-K |
| FY2010 | $-1.05B | -11.1% | 10-K |
| FY2009 | $-941.1M | - | 10-K |